ESMO 2021: TKI treatment breaks for advanced/metastatic kidney cancer – the STAR study
There is increasing interest in using treatment breaks to reduce [...]
Pazopanib for poor risk kidney cancer patients
Pazopanib is used for first-line metastatic RCC treatment, but the [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
Real world use of targeted therapies in war veterans with kidney cancer
A retrospective study of the use of targeted therapies for [...]
Real world use of pazopanib after immunotherapy for advanced kidney cancer
A study published in Clinical Genitourinary Cancer last month describes [...]
Sunitinib and pazopanib for non-clear cell and sarcomatoid kidney cancer
Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell [...]
Metastasectomy followed by targeted therapy does not improve survival
The following video interview with Dr Elizabeth Plimack from the [...]
ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy
In this phase III study, presented at the American Society [...]
Four distinct subgroups of clear cell renal cancer identified
Using gene profiling, a recent study published in Cancer Discovery [...]
